Experimental study on the therapeutic effects of nimustine combined with cisplatin on C6 brain glioma
10.3781/j.issn.1000-7431.2008.11.009
- Author:
Chun-Hua SHE
1
Author Information
1. Department of Neurosurgery and Neuro-oncology
- Publication Type:Journal Article
- Keywords:
Cisplatin;
Drug therapy, combination;
Glioma;
Nimustine
- From:
Tumor
2008;28(11):946-950
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the synergistic effects of nimustine(ACNU) and cisplatin(CDDP) in the treatment of glioma, and investigate the theoretical basis for the combined chemotherapy in clinic. Methods: The cell cycle and apoptosis of C6 glioma cells were examined by flow cytometry after treatment with ACNU plus CDDP for 24 h in vitro. C6 glioma cells were transplanted into the brain of Wistar rats to establish the C6 brain glioma model. The Wistar rats were treated with ACNU plus CDDP for 3 days, and then some rats were sacrificed. Morphological changes of tumor tissues were examined by HE staining. The protein expression of proliferating cell nuclear antigen (PCNA) and apoptosis-associated gene bcl-2 were tested by immunohistochemical method. The survival time of the Wistar rats were observed. Results: The FCM test found that there was no significant difference in cell cycle distribution between combined therapy group and single ACNU therapy group. The apoptotic rate increased after combined therapy [(2.10 ± 0.14)%] compared with single CDDP therapy group [(1.72±0.21)%] and ACNU single therapy group [(0.57±0.01)%]. The difference was significant (P < 0.01). Histological examination revealed the decreased number of the invaded focuses in the margin of the tumor body. Immunohistochemistry analysis indicated that the protein expression levels of PCNA and bcl-2 decreased compared with single therapy group (P < 0.01). The rats in the combined therapy group had longer survival time compared with those received single therapy. The difference was significant (P < 0.01). Conclusion: The combination of ACNU plus CDDP has apparent synergistic effects in the treatment of malignant brain glioma compared with single drug therapy.
